Vor Biopharma scores $42 mln Series A
Boston-based Vor Biopharma, an immuno-oncology company, has secured $42 million in Series A financing. The lead backers were 5AM Ventures and RA Capital Management.
14 February 2019•1 min read
Boston-based Vor Biopharma, an immuno-oncology company, has secured $42 million in Series A financing. The lead backers were 5AM Ventures and RA Capital Management.